Figure 1 | Genetics in Medicine

Figure 1

From: Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study

Figure 1

Absolute risk of receiving adjuvant CT according to the (fully adjusted) linear mixed model in guideline-delineated subgroups of patients within the indicated area for 70-GS use. All patients younger than 70 years of age with ER+/HER2- invasive ductal carcinoma (subgroup A: N0, BRI, >2 cm; subgroup B: N0, BRII, >1 cm; subgroup C: N1mi, BRI/II). CT, chemotherapy; 70-GS, 70-gene signature. *Calculated using the fully adjusted linear mixed model; age, tumor size, invasive tumor grade, axillary involvement, and incidence year were included as covariables in the model. Projected values are the percent chemotherapy use for those without and with the 70-GS as derived from the linear mixed models’ regression equations filled in at the mean of all other covariables for the entire (sub-)group (i.e., the projected difference between 70-GS use and non-use is adjusted for confounding). **P values for interaction between 70-GS use and the subgroups.

Back to article page